Now Playing
Opinion|Videos|September 11, 2024
Navigating Beyond FOLFOX/FOLFIRI: Key Therapies in Advanced mCRC
Medical experts review therapy options for metastatic colorectal cancer after FOLFOX/FOLFIRI, emphasizing regorafenib, FTD/TPI plus or minus bevacizumab, and fruquintinib due to the rarity of targetable biomarkers.
Advertisement
Episodes in this series
Provide a brief overview of our therapy options in metastatic colorectal cancer that has progressed after FOLFOX/FOLFIRI.
- Discuss the importance of biomarker screening.
- A majority of patients will not have targetable biomarkers, so provide emphasis on the 3 therapies: regorafenib, FTD/TPI plus or minus bevacizumab, and fruquintinib.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
